BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($1.83), $0.16 worse than the analyst estimate of ($1.67). Revenue for the quarter came in at $457 thousand versus the consensus estimate of $420.56 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.